Jump to Main Content

ASH Summit on Immunotherapies for Hematologic Diseases

Become an Exhibitor

Become an exhibitor at the ASH Summit on Immunotherapies for Hematologic Diseases. The meeting aims to address why immunotherapies and other targeted therapies impacting immune response fail in different patient populations. Specifically, the Summit will address relevant topics as they relate to both malignant and classical hematologic diseases and will convene various stakeholder groups interested in the use of immunotherapies for malignant and classical diseases including academicians, regulators, and industry researchers. While there are currently several immunotherapy meetings, this ASH Summit provides unique opportunities for companies to engage with investigators conducting emerging areas of research in immunotherapy outside of the cancer field.

Exhibitors will have opportunities to not only participate in the meeting but also build visibility, develop and nurture customer relationships, introduce new products and services, and host presentations (listed as Corporate Presentations in the program schedule) which are designed to provide exhibitors the ability to present new research findings on products, provide product details, and give demonstrations. Corporate presentations are solely promotional in nature and continuing medical education credits will not be offered.

ASH is committed to providing the highest quality meeting possible. It is agreed and understood that these policies for exhibitors are part of a contract between the exhibitor and ASH, and that submission of the Application and Contract for Exhibit Space constitutes the exhibitor’s agreement to abide by these rules and regulations.

All exhibit participants are strongly encouraged to read and be familiar with the ASH Principles for Relations With Industry.

For more information on becoming an exhibitor or to learn about support opportunities, please visit the exhibits website or contact Kristin Hudson at [email protected].

Apply to exhibit

Exhibitor Registration

Exhibitors will receive three complimentary badges. If an additional company representative attends to represent the exhibiting company, they will be required to pay the non-member registration fee.

  • Once an exhibitor is confirmed, the company representative will receive a dedicated registration link to register any/all company representatives for the meeting.
  • ASH does not sell one-day only meeting registrations.

Attendance at Sessions

The complimentary meeting badges allow exhibitors access to the meeting sessions. However, we ask that you not participate in the question-and-answer period during the live sessions.

Eligibility to Exhibit

  • Only an organization identified on a signed Application and Contract for Exhibit Space and approved by ASH may exhibit. The name of the company or organization whose name appears at the top of the Application and Contract for Exhibit Space is eligible to be listed in print and online.
  • ASH retains the exclusive right to determine which companies and organizations may exhibit at ASH meetings.

Cancellation of Meeting

It is mutually agreed that in the event of cancellation of the ASH Summit on Immunotherapies for Hematologic Diseases as a result of strikes, acts of God, war, terrorism, disaster, pandemic, curtailment of transportation facilities, governmental regulations, power or internet outages, technology disruptions or other causes that prevent its scheduled opening or continuance, this agreement will be terminated immediately. ASH shall determine an equitable basis for refund of a portion of the exhibit fee as possible, after due consideration of expenditures and commitments already made.


Small demonstrations are allowed at the tabletop exhibits, but no microphones or sound systems will be allowed.

Amendment by ASH

ASH reserves the right to interpret, amend, and enforce these contract conditions and rules and regulations at any time. Written notice of any amendments or interpretations shall be given to all contracted exhibitors. All amendments that may be made shall be equally binding (upon publication) for all parties as if contained in the original regulation.